These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 23604126)
1. The role of DAB2IP in androgen receptor activation during prostate cancer progression. Wu K; Liu J; Tseng SF; Gore C; Ning Z; Sharifi N; Fazli L; Gleave M; Kapur P; Xiao G; Sun X; Oz OK; Min W; Alexandrakis G; Yang CR; Hsieh CL; Wu HC; He D; Xie D; Hsieh JT Oncogene; 2014 Apr; 33(15):1954-63. PubMed ID: 23604126 [TBL] [Abstract][Full Text] [Related]
2. DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis. Zhou J; Ning Z; Wang B; Yun EJ; Zhang T; Pong RC; Fazli L; Gleave M; Zeng J; Fan J; Wang X; Li L; Hsieh JT; He D; Wu K Cell Death Dis; 2015 Oct; 6(10):e1955. PubMed ID: 26512963 [TBL] [Abstract][Full Text] [Related]
3. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214 [TBL] [Abstract][Full Text] [Related]
5. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Xie D; Gore C; Liu J; Pong RC; Mason R; Hao G; Long M; Kabbani W; Yu L; Zhang H; Chen H; Sun X; Boothman DA; Min W; Hsieh JT Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2485-90. PubMed ID: 20080667 [TBL] [Abstract][Full Text] [Related]
6. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. Ko YJ; Devi GR; London CA; Kayas A; Reddy MT; Iversen PL; Bubley GJ; Balk SP J Urol; 2004 Sep; 172(3):1140-4. PubMed ID: 15311058 [TBL] [Abstract][Full Text] [Related]
7. Expression profiles and functional associations of endogenous androgen receptor and caveolin-1 in prostate cancer cell lines. Bennett NC; Hooper JD; Johnson DW; Gobe GC Prostate; 2014 May; 74(5):478-87. PubMed ID: 24375805 [TBL] [Abstract][Full Text] [Related]
8. The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth. Tsai YS; Lai CL; Lai CH; Chang KH; Wu K; Tseng SF; Fazli L; Gleave M; Xiao G; Gandee L; Sharifi N; Moro L; Tzai TS; Hsieh JT Oncotarget; 2014 Aug; 5(15):6425-36. PubMed ID: 25115390 [TBL] [Abstract][Full Text] [Related]
9. DAB2IP regulates intratumoral testosterone synthesis and CRPC tumor growth by ETS1/AKR1C3 signaling. Gu Y; Wu S; Chong Y; Guan B; Li L; He D; Wang X; Wang B; Wu K Cell Signal; 2022 Jul; 95():110336. PubMed ID: 35452821 [TBL] [Abstract][Full Text] [Related]
10. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells. Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555 [TBL] [Abstract][Full Text] [Related]
11. Prosaposin is an AR-target gene and its neurotrophic domain upregulates AR expression and activity in prostate stromal cells. Koochekpour S; Lee TJ; Sun Y; Hu S; Grabowski GA; Liu Z; Garay J J Cell Biochem; 2008 Aug; 104(6):2272-85. PubMed ID: 18481277 [TBL] [Abstract][Full Text] [Related]
12. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP). Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040 [TBL] [Abstract][Full Text] [Related]
13. Interleukin-4 in patients with prostate cancer. Takeshi U; Sadar MD; Suzuki H; Akakura K; Sakamoto S; Shimbo M; Suyama T; Imamoto T; Komiya A; Yukio N; Ichikawa T Anticancer Res; 2005; 25(6C):4595-8. PubMed ID: 16334148 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens. Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth. Mashima T; Okabe S; Seimiya H Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811 [TBL] [Abstract][Full Text] [Related]
16. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Cao X; Qin J; Xie Y; Khan O; Dowd F; Scofield M; Lin MF; Tu Y Oncogene; 2006 Jun; 25(26):3719-34. PubMed ID: 16449965 [TBL] [Abstract][Full Text] [Related]
17. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms. Brys M; Stawinska M; Foksinski M; Barecki A; Zydek C; Miekos E; Krajewska WM Oncol Rep; 2004 Jan; 11(1):219-24. PubMed ID: 14654929 [TBL] [Abstract][Full Text] [Related]
18. Prosaposin is a novel androgen-regulated gene in prostate cancer cell line LNCaP. Koochekpour S; Lee TJ; Wang R; Sun Y; Delorme N; Hiraiwa M; Grabowski GA; Culig Z; Minokadeh A J Cell Biochem; 2007 Jun; 101(3):631-41. PubMed ID: 17171640 [TBL] [Abstract][Full Text] [Related]
19. Phenethyl isothiocyanate inhibits androgen receptor-regulated transcriptional activity in prostate cancer cells through suppressing PCAF. Yu C; Gong AY; Chen D; Solelo Leon D; Young CY; Chen XM Mol Nutr Food Res; 2013 Oct; 57(10):1825-33. PubMed ID: 23661605 [TBL] [Abstract][Full Text] [Related]
20. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer. Shiota M; Yokomizo A; Naito S Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]